2021

  1. Adalimumab in paediatric UC

  2. Etrolizumab vs infliximab in UC

  3. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial

  4. Low-Fat, High-Fiber Diet Reduces Markers of Inflammation and Dysbiosis and Improves Quality of Life in UC

  5. IFX induction TDM or standard of care

  6. IFX maintenance TDM or standard of care